Oxford BioMedica licenses out vax tech in $21.4M deal; Hemispherx wins $188M judgment; Immunogen gains orphan status;

 @FierceBiotech: Biogen pays $80M to buddy up on PhIII ALS program. Story | Follow @FierceBiotech

 @JohnCFierce: If I were in Alzheimer's R&D, I'd be scared right down to my boots. Talk about flying blind. | Follow @JohnCFierce

> The UK's Oxford BioMedica says it inked a deal to license vaccine development technology to Emergent Biosolutions for up to $21.4 million. Emergent plans to use the technology to develop up to eight vaccines, including one for tuberculosis. Oxford collected a $1 million fee on the deal. Report

> Hemispherx Biopharma says it won a $188M judgment in a federal lawsuit filed against South Africa's JCI along with one of its directors and the estate of a former officer of the company. The Philadelphia-based developer had alleged the defendants had fraudulently obtained insider information on the company in order to devalue its stock price. But the judgment may be hard to collect. Report

> Immunogen says it won orphan drug status for lorvotuzumab mertasine, a drug for small cell lung cancer. Article

> Xconomy reports that the Institute for Systems Biology plans to move to Seattle's South Lake Union area. Story

And Finally... It's unavoidable: breakdowns in brain connections slow down our physical response times as we age, a new study suggests. Release

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.